CytoMed Therapeutics hits early ANGELICA trial milestone, starts Dose 2

Rhea-AI Filing Summary

CytoMed Therapeutics (GDTC) filed a Form 6-K to furnish a 21 Jul 2025 press release. The company has completed Dose Level 1 of its first-in-human Phase I dose-escalation “ANGELICA” trial of CTM-N2D, an investigational cell therapy for patients with advanced solid tumours or haematological malignancies, and has been cleared to begin Dose Level 2. The milestone indicates initial safety/tolerability at the starting dose, a prerequisite for further escalation and eventual efficacy assessment.

The filing contains no financial data, guidance, or corporate transactions; its sole purpose is to publicly disclose this clinical progress (Exhibit 99.1). Investors should view the news as an early-stage, non-pivotal signal of programme momentum rather than a determinant of near-term revenue.

Positive

• Successful completion of Dose Level 1 indicates initial safety/tolerability of CTM-N2D.
• Regulatory clearance to proceed to Dose Level 2 keeps the Phase I trial on schedule and maintains development momentum.

Negative

• No efficacy or detailed safety data were provided, limiting assessment of clinical value.
• Milestone is early-stage; extensive development, capital, and regulatory hurdles remain.

Insights

Biotech Industry Specialist

TL;DR – Dose Level 1 completion signals acceptable safety; positive but very early-stage.

The transition to Dose Level 2 confirms CTM-N2D met predefined safety criteria at the starting dose, de-risking the programme’s first hurdle. For small-cap developers, any forward movement in first-in-human studies can catalyse sentiment and non-dilutive partnership interest. However, absence of efficacy data and the limited cohort size typical of Phase I means valuation impact is speculative. I view the disclosure as modestly positive and potentially price-moving for GDTC’s thinly traded shares.

Risk Analyst

TL;DR – Early milestone; risk profile remains high until later-stage readouts.

Completion of the first dosing cohort reduces immediate safety uncertainty but leaves substantial clinical, regulatory, and financing risk. The filing lacks detail on adverse events or cohort size, limiting analytical depth. With no accompanying balance-sheet update, cash runway and dilution risk are unchanged. Overall impact is neutral-to-positive; meaningful re-rating depends on multi-dose safety and preliminary efficacy signals.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2025

Commission File Number: 001-41677

CytoMed Therapeutics Limited

(Exact name of registrant as specified in its charter)

1 Commonwealth Lane

#08-22

Singapore 149544

(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

On July 21, 2025, CytoMed Therapeutics Limited (the “Company”) issued a press release announcing that the Company has completed Dose Level 1 of its first-in-human Phase I dose-escalation clinical trial of CTM-N2D (“ANGELICA Trial”), and is proceeding to Dose Level 2.

A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K.

Exhibits

Exhibit No.		Description
99.1		Press Release dated July 21, 2025 titled: Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CytoMed Therapeutics Limited
Date: July 21, 2025	By:	/s/ CHOO Chee Kong
		CHOO Chee Kong Director and Chairman

FAQ

What did CytoMed Therapeutics (GDTC) report in its July 21 2025 Form 6-K?

The filing states that GDTC completed Dose Level 1 of its Phase I ANGELICA trial for CTM-N2D and will start Dose Level 2.

What is the ANGELICA trial?

ANGELICA is a first-in-human Phase I dose-escalation study of CTM-N2D in patients with advanced solid tumours or haematological malignancies.

Does the Form 6-K include financial results or guidance?

No. The document only furnishes a clinical milestone press release and contains no financial figures.

Why is completing Dose Level 1 important for GDTC?

It confirms initial safety, allowing escalation to higher doses, a key step toward assessing efficacy and advancing the asset’s development.

What is the next step after Dose Level 1 for CTM-N2D?

The company will enroll patients at Dose Level 2, continuing safety monitoring before potentially moving to higher doses.